Finance

Lists
4559:TYO
Zeria Pharmaceutical Co Ltd
¥2,008.00
-0.30%
(-6.00) 1D
Sep 16, 3:30:00 PM GMT+9  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 4559...
Open
¥2,014
High
¥2,025
Low
¥2,008
Mkt. cap
100.64B
Avg. vol.
139.62K
Volume
86.90K
Dividend
2.44%
Quarterly dividend
¥12
Ex-dividend date
Sep 29, 2026
P/E ratio
10.75
52-wk high
¥2,434
52-wk low
¥1,878
EPS
¥187
Shares outstanding
50.11M
No. of employees
2K
Open
¥2,014
High
¥2,025
Low
¥2,008
Mkt. cap
100.64B
Avg. vol.
139.62K
Volume
86.90K
Dividend
2.44%
Quarterly dividend
¥12
Ex-dividend date
Sep 29, 2026
P/E ratio
10.75
52-wk high
¥2,434
52-wk low
¥1,878
EPS
¥187
Shares outstanding
50.11M
No. of employees
2K
Profile
Zeria Shinyaku Kōgyō KK is a Japanese drug manufacturer that obtained Tillotts Pharma AG. In 1955, the Japanese Kisaku Ibu, former Yamanouchi Seiyaku executive opened a new pharmaceutical company in Tokyo under the name Zeria Yakushō Kenkyusho. In 1970, this company becomes Zeria Shinyaku Zeria Shinyaku KK. In 1975, it built a new factory in Kumagaya in Saitama prefecture, before the main factory in Tsukuba which was constructed by Takenaka Corporation in 1988. In 2009, the company obtained Switzerland company Tillotts Pharma AG, and began operating internationally through a large network of subsidiaries, It manufactures and sells pharmaceuticals in Sweden, Ireland, UK, Czech Republic, Spain, Germany, France, Italy, Vietnam and Denmark. The drug itself is developed in Switzerland, Tillotts Parma. The company owns a 6.63% share of Asuka Seiyaku, also a pharmaceutical company, other than its subsidiaries. The main shareholder of the company is the company itself, the present president Mitsuhiro Ibu, Mitsubishi UFJ Financial Group, Custody Bank of Japan, Morinaga Milk Industry, SMBC, Mizuho Bank, Risona Bank, Aioi Nissay Dowa Insurance as of March 2023. Wikipedia
About Zeria Pharmaceutical Co Ltd
CEOSachiaki Ibe
Employees1.75K
FoundedDec 22, 1955
Headquarters-
SectorPharmaceutical industry
Websitezeria.co.jp
Previous reportsAll values in JPY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in JPY
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
20.47B
24.12B
25.08B
21.45B
Cost of goods sold
5.59B
6.38B
6.43B
6.22B
Cost of revenue
5.59B
6.38B
6.43B
6.22B
Research and development expenses
-
-
3.71B
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
12.76B
12.82B
4.85B
13.28B
Operating expense
12.76B
12.82B
14.84B
13.28B
Total operating expenses
18.35B
19.19B
21.27B
19.50B
Operating income
2.12B
4.93B
3.81B
1.95B
Other non operating income
-23.00M
-81.04M
305.04M
-47.28M
EBT including unusual items
994.00M
4.63B
3.92B
1.43B
EBT excluding unusual items
994.00M
4.63B
3.76B
1.43B
Income tax expense
383.00M
795.44M
979.56M
547.57M
Effective tax rate
38.53%
-
25.02%
38.21%
Other operating expenses
-
-
-
-
Net income
647.00M
3.82B
2.90B
866.20M
Net profit margin
3.16%
-
11.56%
4.04%
Earnings per share
-
-
-
-
Interest and investment income
30.00M
136.71M
32.29M
305.03M
Interest expense
-119.00M
-123.00M
-138.00M
-132.04M
Net interest expenses
-89.00M
13.71M
-105.71M
172.99M
Depreciation and amortization charges
-
-
5.78B
-
EBITDA
3.88B
6.81B
5.65B
4.24B
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps